STUB1 and cancer: In patients with primary solid cancer who are planning to undergo cytotoxic chemotherapy, radiotherapy, or RAIT, initial assessment with germline mutation testing using an expanded NGS panel comprising low-, moderate-, and high-risk cancer-associated genes and somatic CHIP mutation testing can give clue to the patients who are at risk of developing therapy-related myeloid and lymphoid malignancies.